Embedded Files
Targeted Drug Delivery for Transformational Therapeutics
Lanuaria Therapeutics is developing transformational drugs to redefine patient outcomes beginning with 3 product candidates for hard-to-treat solid cancers. Our proprietary platform enables us to develop drugs with superb efficacy and safety, all while leaving healthy tissues unharmed.
For most drugs, only a fraction of a dose ends up where it’s needed.
This has dramatic ramifications for both patients and drug developers.
We need a new standard of care, one focused on targeted drug delivery to a disease site that improves efficacy, decreases toxicity, and reduces the costs of drug development and manufacturing.
It’s why we built Lanuaria
A proprietary platform to generate novel drugs that actually accumulate in targeted tissues, with an ability to administer small doses with superb efficacy and safety
Based on small molecule ligands for small-sized therapeutics
Specific and strong target binding
Long half-life optionality
Deploy a variety of mechanisms of action (MOAs)
Designed for therapeutic payload versatility
Report abuse